Kepivance: profile and news

Amgen's Fourth Quarter 2005 Adjusted Earnings Per Share Increased ...  Jan 26, 2006
Kepivance (palifermin): The Company announced that Kepivance received regulatory approval in the European Union to decrease the incidence, duration and ... - Biotech Intelligence (press release),

Lilly's Gemzar For Ovarian Cancer To Receive Oncologics Cmte. ...  Jan 19, 2006
...of its Pediatric Oncology Subcommittee, which discussed pediatric study commitments for Genzyme’s Clolar, Amgen’s Neulasta and Kepivance, and pediatric ... - FDA Advisory Committee

New Cancer Drugs, Azacitidine and Kepivance, Benefit Patients but ...  Nov 14, 2005
Kepivance, which is a human keratinocyte growth factor produced by recombinant DNA technology in Escherichia coli, is currently under investigation for ... - DG News

Reyataz, Lunesta Win MM&M Gold Awards  Nov 14, 2005
An honorable mention for the category went to Amgen and Abelson-Taylor for their work on the launch of Kepivance. The MM&M Awards, presented Wednesday, Nov. ... - Business Wire (press release),

Cancer drug boom projected  Sep 19, 2005
...sector. Amgen has four oncology drugs on the market, including Aranesp, Neupogen, Neulasta and Kepivance, and nine in its pipeline. ... - CNN

Outlook is good for TO's Amgen  Aug 21, 2005
Amgen started this year with new drug Kepivance, which received US Food and Drug Administration approval at the end of 2004. Kepivance ... - Ventura County Star (subscription),

Tanox Names Linda Paradiso Vice President of Clinical Operations ...  Aug 15, 2005
...directly to the worldwide development and lifecycle management of Viracept(R), Penetrex(R), Omnicef(R), Doxil(R), DepoCyt(R), Kepivance(TM), Neulasta(TM) and ... - PR Newswire (press release),